DRIVIN' CAR: Developing robust in vivo nanomedicine-based chimeric antigen receptor technologybroad
DRIVIN CAR · Horizon Europe grant · 2026-03-01–2030-02-28
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2025-PATHFINDEROPEN · scheme HORIZON-EIC · topic HORIZON-EIC-2025-PATHFINDEROPEN. CORDIS record →
Objective
DRIVIN’ CAR aims to transform immunotherapy by developing a scalable, cost-effective platform for in vivo generation of chimeric antigen receptor (CAR) immune cells. Using proprietary apolipoprotein nanoparticle (aNP) platform technology, DRIVIN’ CAR pursues robust CAR monocyte/macrophage (CAR M) and CAR T cell therapy. Owing to their biocompatibility and natural tropism for myeloid cells, aNPs are excellently suited for in vivo CAR M therapy. For efficient in vivo T cell targeting, aNPs can be modularly surface-functionalized with apolipoprotein fusion proteins.The Program’s aNP platform technology addresses key limitations of current CAR therapies that prevent widespread implementation. It simultaneously tackles high treatment costs, complex ex vivo manufacturing procedures, and poor performance in solid tumors of conventional CAR cell therapy. The aNP platform also overcomes challenges associated with emerging in vivo approaches, such as limited specificity and safety risks.By combining advanced bioengineering, high throughput manufacturing, library screening approaches and in vivo validation, DRIVIN’CAR brings together world-leading experts to deliver a unique and versatile platform for in vivo CAR therapies with real clinical impact.This Program’s successful completion will advance the aNP platform to TRL 4. Besides enabling in vivo CAR immune cell therapy for cancer treatment, the aNP platform has significant translational potential and pertinency for applications in non-malignant diseases such as autoimmune disorders and cardiovascular disease.
Beneficiaries (6)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| TECHNISCHE UNIVERSITEIT EINDHOVEN | NL | coordinator | €550,217 | |
| VRIJE UNIVERSITEIT BRUSSEL | BE | participant | €550,625 | |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | NL | participant | €550,000 | |
| UNIVERSITAETSKLINIKUM AACHEN | DE | participant | €549,750 | |
| BIO-TRIP B.V. | NL | participant | €549,271 | Yes |
| NANOWORX B.V. | NL | participant | €250,483 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.